Injection of active vitamin D is associated with better survival of patients receiving chronic hemodialysis. Since in many countries oral active vitamin D administration is the most common form of treatment for secondary hyperparathyroidism we determined the survival benefit of oral active vitamin D in hemodialysis patients from six Latin America countries (FME Registers as part of the CORES study) followed for a median of 16 months. Time-dependent Cox regression models, after adjustment for potential confounders, showed that the 7,203 patients who received oral active vitamin D had significant reductions in overall, cardiovascular, infectious and neoplastic mortality compared to the 8,801 patients that had not received vitamin D. Stratified analyses found a survival advantage in the group that had received oral active vitamin D in 36 of the 37 strata studied including that with the highest levels of serum calcium, phosphorus and parathyroid hormone. The survival benefit of oral active vitamin D was seen in those patients receiving mean daily doses of less than 1 lg with the highest reduction associated with the lowest dose. Our study shows that hemodialysis patients receiving oral active vitamin D had a survival advantage inversely related to the vitamin dose.
Injection of active vitamin D is associated with better survival of patients receiving chronic hemodialysis. Since in many countries oral active vitamin D administration is the most common form of treatment for secondary hyperparathyroidism we determined the survival benefit of oral active vitamin D in hemodialysis patients from six Latin America countries (FME Registers as part of the CORES study) followed for a median of 16 months. Time-dependent Cox regression models, after adjustment for potential confounders, showed that the 7,203 patients who received oral active vitamin D had significant reductions in overall, cardiovascular, infectious and neoplastic mortality compared to the 8,801 patients that had not received vitamin D. Stratified analyses found a survival advantage in the group that had received oral active vitamin D in 36 of the 37 strata studied including that with the highest levels of serum calcium, phosphorus and parathyroid hormone. The survival benefit of oral active vitamin D was seen in those patients receiving mean daily doses of less than 1 lg with the highest reduction associated with the lowest dose. Our study shows that hemodialysis patients receiving oral active vitamin D had a survival advantage inversely related to the vitamin dose. Calcitriol deficiency is a common medical condition among patients with chronic kidney disease. 1, 2 Calcitriol, the most active form of vitamin D, increases intestinal calcium absorption, effectively suppresses parathyroid hormone (PTH) secretion, prevents skeletal complications, and it has been the standard therapy for secondary hyperparathyroidism for more than two decades. 3 Calcitriol administration may also result in an elevation of serum calcium and phosphorus levels, which may facilitate vascular calcification and death. 4 Conversely, other studies have shown that the use of calcitriol and other forms of vitamin D derivatives is associated with improved survival in patients with cancer or infections. [5] [6] [7] More recently, a large historical cohort study has demonstrated a significant survival advantage of 20% in chronic hemodialysis patients receiving injectable active vitamin D. 8 In many countries, the most common form of administration of active vitamin D as treatment for secondary hyperparathyroidism is the oral route instead of the injectable form. Accordingly, this study examined the potential survival effect of oral active vitamin D in a large cohort of hemodialysis patients.
RESULTS
Baseline characteristics of the group that received oral active vitamin D (n ¼ 7203) and the group that did not receive it (n ¼ 8801) are shown in Table 1 . Baseline serum levels of phosphorus and calcium-phosphorus product were significantly lower, whereas PTH was higher in the oral active vitamin D users. Patients who did not receive oral active vitamin D were older; and there were more diabetics. Throughout the whole follow-up there were 3110 deaths and 1792 lost to follow-up due to: renal transplantation (39.0%), switch to peritoneal dialysis (29.5%), voluntary withdrawal from therapy (16.1%), recovery of renal function (9.6%), unknown circumstances (3.7%), and transfer to a non-Fresenius dialysis unit (2.1%).
(14.6%); and Colombia (13.8%). The crude analysis using the Kaplan-Meier curve showed significant reduction of mortality risk in patients who received oral active vitamin D within 1 year compared to these who did not receive it (Po0.001, Figure 1) . As the Figure 2 shows, the association of oral active vitamin D use with mortality reduction did not vary by country, including countries with both high and low overall death rates.
As primary exposure was time dependent and the Kaplan-Meier curve might have overestimated the survival benefit, additional analyses (models 2-5 in Table 2 ) were carried out after adjustment for potential confounders. There were no differences between the adjusted and unadjusted mortality risk among those patients who did and did not receive vitamin D therapy. Multivariable adjusted analyses revealed that patients who received oral active vitamin D had a significant 45% (hazard ratio, 0.55; 95% confidence interval (CI), 0.49-0.63) lower overall mortality risk compared to patients who did not receive oral active vitamin D (Table 2) . Furthermore, cardiovascular, infectious, and neoplastic mortality risk were 45 (hazard ratio, 0.55; CI, 0.45-0.67), 48 (hazard ratio, 0.52; CI, 0.39-0.68), and 47% (hazard ratio, 0.53; CI, 0.34-0.82) lower, respectively, in patients on oral active vitamin D.
Similar results were observed when center instead of country was used as covariate in the multivariate analysis.
As once the patient was withdrawn from hemodialysis, no additional information about mortality was obtained, a Baseline time on dialysis, parathyroid hormone and ferritin represent the median and interquartile range. In the case of the parathyroid hormone, the median and interquartile range were obtained over 6 months. A Mann-Whitney U-test has been made for comparison between groups.
sensitivity analysis was carried out to examine the potential impact of the censored patients. The sensitive analysis revealed that censored patients (hazard ratio, 0.58; CI, 0.51-0.67) did not differ from those who were not censored (hazard ratio, 0.55; CI, 0.49-0.63) and the association of vitamin D with reduced mortality did not differ when participants were considered to have died at the time of censoring (hazard ratio, 0.58; CI, 0.53-0.65). The 244 patients censored, because they switched from oral active vitamin D to injectable active vitamin D, also showed a survival benefit (hazard ratio, 0.63; CI, 0.42-0.93).
The analysis of prevalent and incident hemodialysis patients showed also a significant reduction in the mortality risk rates in both groups. Overall mortality (hazard ratio, prevalent: 0.51; CI, 0.40-0.66 and hazard ratio, incident: 0.57; CI, 0.50-0.67), cardiovascular mortality (hazard ratio, prevalent: 0.59; CI, 0.40-0.88 and hazard ratio, incident: 0.53; CI, 0.42-0.67), infectious mortality (hazard ratio, prevalent: 0.61; CI, 0.37-1.02 and hazard ratio, incident: 0.50; CI, 0.38-0.75), and neoplastic mortality (hazard ratio, prevalent: 0.33, CI, 0.13-0.84 and hazard ratio, incident: 0.56; CI, 0.34-0.75). The association of vitamin D with reduced mortality was not altered when socioeconomic status was added to analyses in a subset of participants with available data (n ¼ 6961 from Argentina).
Stratified analysis
As it has been mentioned, certain baseline characteristics differed between the two groups ( Table 1) . Patients who received oral active vitamin D treatment were 1.7 years younger with a 4.2% lower prevalence of diabetes. Other baseline characteristics such as body weight, serum creatinine, serum albumin, and serum hemoglobin levels were higher in patients who received oral active vitamin D treatment. In order to minimize the confounding effect of these baseline differences, we performed stratified analyses ( Figure 2 ). Within each level of the stratified variables, the analysis was multivariable adjusted for all the potential confounders included in the final model shown in Table 2 . In 36 of the 37 strata studied, we observed a significant survival advantage in the group that had received oral active vitamin D, including the stratum of patients with the highest serum calcium (tertile 3: 49.37 mg per 100 ml), phosphorus (tertile 3: 45.33 mg per 100 ml), and PTH levels (tertile 3: 4326 pg/ml). The stratification of the propensity score in tertiles confirmed a significant survival advantage in the group that had received oral active vitamin D (tertile 1-hazard ratio: 0.65, CI: 0.51-0.83; tertile 2-hazard ratio: 0.51, CI: 0.41-0.65; tertile 3-hazard ratio: 0.44, CI: 0.35-0.55).
Secondary analysis
To further examine the effect of different doses of oral active vitamin D, we analyzed the results of the four preestablished categories using unadjusted and adjusted analyses, using as covariates all those included in model 5 in Table 2 . Patients who received oral active vitamin D in a mean daily dose lower than 0.25 mg, between 0.25-0.50 mg, and 0.51-1 mg showed a mortality reduction of 54% (hazard ratio, 0.46; CI, 0.39-0.54), 42% (hazard ratio, 0.58; CI, 0.49-0.70), and 36% (hazard ratio, 0.64; CI, 0.50-0.83), respectively. However, no significant reduction in mortality was observed with a mean daily dose higher than 1 mg (hazard ratio, 0.83; CI, 0.58-1.19; Figure 3 ). In the lower dose group (o0.25 mg) the cumulative dose was 78 mg and the duration of treatment was 540 days, meanwhile in the highest dose group (41 mg) the cumulative dose was nine times higher (686 mg) and the duration of treatment shorter (314 days).
We also performed independent analyses in those patients whom the current clinical practice K/DOQI guidelines recommended the use of active vitamin D metabolites (baseline intact PTH 4300 pg/ml and Calcium-Phosphorus product o55 mg 2 per (100 ml) 2 ). 9 A mean daily dose lower than 0.25 mg (mean 0.15 mg) and also a dose between 0.25 and 0.50 mg (mean 0.34 mg) significantly reduced the mortality risk rate by 55% (hazard ratio, 0.45; CI, 0.31-0.65) and by 60% (hazard ratio, 0.40; CI, 0.27-0.60), respectively, compared to oral active vitamin D nonusers. No significant reduction in mortality risk was found in patients receiving either a mean daily dose between 0.51 and 1 mg (mean 0.67; hazard ratio, 0.77; CI, 0.49-1.23) or a dose of more than 1 mg (mean 1.69; hazard ratio, 1.14; CI, 0.56-2.33). The analyses of prevalent and incident patients showed similar patterns; however, patients who started oral active vitamin D treatment within the first 90 days showed a slightly better results than patients who started the treatment later (hazard ratio, 0.57; CI, 0.48-0.68 vs hazard ratio, 0.74; CI, 0.62-0.87, respectively).
DISCUSSION
In the past few years, the detrimental or beneficial effect of active vitamin D treatment on the cardiovascular system and the risk of mortality has been a controversial issue. The concern about the harmful effect of vitamin D derivatives is mainly based on the fact that in experimental models high doses of vitamin D metabolites have shown to increase vascular calcifications 10, 11 and some human data also support this notion. 12 On the other hand, experimental studies have shown that low and more physiological dose of active vitamin D may have a cardioprotective effect.
13,14 Observational The baseline values quoted were weight, albumin, creatinine, and hemoglobin. In addition, one epidemiological study reported a survival advantage when patients receiving new vitamin D analogs were compared to patients receiving an injectable calcitriol formulation. 19 However, this effect was less pronounced in a recent paper. 18 It was speculated that the potential survival advantage was mediated by the described less calcemic and phosphatemic effects of the new analogs, but the survival benefit was sustained for almost all levels of phosphorus and calcium. 18, 19 Although oral active vitamin D treatment is widely used, till date there is only one paper investigating survival using oral active vitamin D in a small cohort of patients. 16 The results of our study show for the first time a significant survival advantage of oral active vitamin D in a larger cohort of chronic hemodialysis patients. Similarly to others, 8 this advantage of oral active vitamin D appeared to be independent of other potential risk factors and confounders. In fact, the reduction in mortality risk was observed in 36 of the 37 multivariate strata analyzed, including baseline serum calcium, phosphorus, and PTH levels. The only stratum which did not achieve statistical significance was the one related to the use of grafts as vascular access, possibly due to the low number of patients.
Despite the potentially higher bioavailability of the injectable form of vitamin D compared to the oral form, our data show a higher reduction in the overall mortality risk compared to the results obtained with injectable active vitamin D. 8 The biological significance on survival benefit for oral active vitamin D users merits a detailed analysis.
The positive results in all causes of mortality suggest that the beneficial effect of active vitamin D is beyond its effect on calcium-phosphorus metabolism. In recent years, several experimental studies have demonstrated, among other actions, an important role of active vitamin D in the suppression of cell growth and regulation of immune response. 20, 21 Moreover, nutritional and epidemiological evidence has linked abnormalities in the vitamin D system to susceptibility to infections, autoimmune diseases, and cancer. [22] [23] [24] Similarly in our study, neoplastic and infectious mortality were significantly reduced (47 and 48%, respectively) in patients receiving oral active vitamin D. Moreover, for neoplastic mortality risk this effect was more marked in patients who spent more time on dialysis (prevalent hemodialysis patients, 67%; incident hemodialysis patients, 44%), suggesting a long-term benefit of active oral vitamin D.
Besides these positive survival effects, the benefit of oral active vitamin D for the cardiovascular system is a controversial issue. It is well known that high doses of active vitamin D increase serum calcium and serum phosphorus, and also suppress serum PTH favoring through different mechanisms vascular calcification and mortality. [10] [11] [12] 25, 26 Conversely, physiological doses of active vitamin D have shown protective cardiovascular effects reducing the inflammatory response to cardiovascular injury, the myocardial cell hypertrophy and proliferation, and the renin-angiotensin system activation. 27 As it has been said, part of these paradoxical effects of vitamin D can be explained by the different dose of active vitamin D used. High pharmacological doses may favor and precipitate vascular calcifications whereas more physiological doses may have protective effects.
Our study shows that mean daily doses of oral active vitamin D lower than 1 mg showed a significant benefit in survival rate. Interestingly, the reduction in mortality risk was even seen at the lowest PTH tertile where a tendency to a higher mortality risk has been described, 28 and also, like others, with high serum and phosphorus levels. 19 In fact, a mean daily dose of oral active vitamin D lower than 0.25 mg was able to reduce the mortality risk by 53% in patients with PTH lower than 150 pg/ml (hazard ratio, 0.47; CI, 0.33-0.66) independently of serum calcium or phosphorus levels (data not shown). On the contrary, higher doses of oral active vitamin D did not have any effect in survival probably, in part, due to the increments in serum phosphorus levels observed in this group. In fact, during the whole follow-up period the mean phosphorus levels of the higher dose group was significantly higher (5.34 ± 1.24 mg per 100 ml) than the other groups. This fact may partially explain the greater survival benefit with intravenous paricalcitol compared to calcitriol found in previous studies. 19 Similarly, other authors have found a dose-dependent beneficial effect with paricalcitol with the lowest doses, 17 potency equivalent with the daily dose of our study. However, it is necessary also to consider that in our study the reduced number of patients in the higher dose group is a limitation in order to give a strong value to this finding.
There were some differences in the results obtained in incident and prevalent patients. Prevalent patients were younger (52 (16) vs 56 (16) years old) and obtained benefits in survival with doses of oral active vitamin D up to 1 mg per day, whereas in incident patients the beneficial effect was seen only up to 0.50 mg per day. In addition, prevalent patients also showed better outcomes regarding neoplastic mortality compared to incident patients. Regarding the doses, the whole set of results is consistent with the fact that lower doses which results in lower cumulative dose of oral active vitamin D are associated with more benefits in survival despite a more prolonged time of exposure.
The survival benefit of oral active vitamin D treatment were consistent in all centers and across countries despite the differences in mortality rates within each country described in the results.
Our study shows for the first time a survival beneficial effect of oral active vitamin D in a large cohort of hemodialysis patients followed up to 4 years, however, these interesting and encouraging results may have some limitations. It could have happened that patients with lower calcitriol and calcidiol serum levels were those who benefited most from oral active vitamin D treatment. Nevertheless, even if this would have been the case, we still can claim a benefit of oral active vitamin D for all patients. Our study cannot rule out a possible influence of 25(OH)D 3 (calcidiol) levels, a form of vitamin D that has-among others-also been related to improved outcomes. 29, 30 The patients included in our study did not receive this form of vitamin D, and serum calcidiol and calcitriol levels were not measured. Calcidiol insufficiency has been reported worldwide but there are no studies evaluating mortality.
Although, at baseline the mean serum calcium and phosphorus was significantly higher and the PTH lower in the non-oral active vitamin D users, this fact is expected in studies of large populations even though the magnitude of the differences are small. Clinically relevant differences were only present when there were differences in PTH (Figure 2) . In any case, these findings reflect that oral active vitamin D was adequately prescribed, as patients with moderately high levels of serum calcium and phosphorus and with no important serum PTH elevations did not receive oral active vitamin D treatment. In fact, the mean daily dose of oral active vitamin D used was related with the median serum PTH levels as stated in Figure 3 .
We are also aware that some measured (Table 1) and unmeasured confounders (such as bone turnover markers, vascular calcification, inflammatory status, vitamin D receptor gene polymorphisms, or even socioeconomic status-only marginally addressed in this study), or other biases favoring the vitamin D-treated group cannot be completely excluded, despite the complete strata analysis carried out. Even considering the consistent results obtained using the propensity score, we cannot fully exclude some effect of confounding by indication, a common limitation in observational studies. In fact, the risk for confounding by indication may be increased by use of covariate data obtained at baseline rather than at the time of vitamin D initiation. Although a sensitivity analysis was carried out, it does not fully compensate the missing mortality data from part of the study population. Finally, even though it was not possible to standardize mortality, the adjustment by country and center should have balanced the results.
In summary, our study found that hemodialysis patients receiving oral active vitamin D showed a survival advantage. This biological benefit was seen after several stratified analyses, including different strata of calcium, phosphorus, and PTH levels and it seems to be inversely related to the vitamin D dose, observing a better survival with the lower doses.
MATERIALS AND METHODS
The study was performed in a historical cohort of chronic hemodialysis patients from six Latin American countries (Argentina, Brazil, Colombia, Chile, Mexico, and Venezuela) from the CORES study (Control of Renal Osteodystrophy in South America), who started hemodialysis, three times a week (98.8%) and two times a week (1.2%), in 183 different dialysis facilities associated or operated by Fresenius Medical Care. The entire study population (n ¼ 22,230) consisted of patients older than 18 years who either initiated hemodialysis (incident patients-72.4% of the cohort) or were already on hemodialysis (prevalent patients-27.6% of the cohort) after 1 January 2000. Patients were followed for a period of time between 3 and 54 months (median 16 months) until 30 June 2004 or until they were lost to follow-up.
During the study period and once the patient was admitted to the hemodialysis center, demographic, clinical, laboratory, and other general data were collected prospectively and entered into a central database updated by medical personnel and stored by Fresenius Medical Care (FME register). From this database, the following data were analyzed: age, gender, weight, country, date of first dialysis, vascular access, primary cause of renal failure, dose of dialysis, medications administered during each hemodialysis session (name, date, dose, and route of administration), laboratory tests, and comorbidities occurring throughout the follow-up period. All missed hemodialysis treatments (for example, because of hospitalization or noncompliance) and all permanent discharges (for example, transplantation, voluntary withdrawal from therapy, transfer to a non-Fresenius dialysis unit, change to peritoneal dialysis, or lost to follow-up) were also analyzed. Deaths were defined using the International Classifications of Diseases (ICD-10) and they were grouped and classified according to the Table 3 .
The non-aluminic phosphate binders used in this study were calcium acetate and calcium carbonate; neither sevelamer nor lanthanum carbonate were used. All the collected data were checked prospectively to ensure their accuracy and completeness. The study met the privacy standards implements by Fresenius with a waiver for informed consent. were excluded from the analysis. Therefore, this study includes only the analysis of patients receiving calcitriol or alphacalcidol referred in the paper as 'oral active vitamin D' . For the follow-up, data were censored if patients changed from oral active vitamin D to injectable active vitamin D type (n ¼ 244), but not if vitamin D was interrupted or discontinued. Also 6057 (27.2%) patients who remained less than 90 days on chronic hemodialysis were excluded from the analysis. The reasons for these exclusions were: beginning of hemodialysis after April 2004 (41.8%); death (29.3%); switch to peritoneal dialysis (11.5%); recovery of renal function (7.1%); voluntary withdrawal from therapy (4.7%); unknown circumstances (3.3%); and renal transplantation (2.3%).
During the entire study period, 7203 (45.0%) of the 16,004 remaining patients received oral active vitamin D. Among them, 6962 patients (96.7%) received calcitriol (Rocaltrol, Roche Pharmaceuticals, Nutley, New Jersey, USA and Calcitriol Purissimus, Buenos Aires, Purissimus, Argentina), 212 patients (2.9%) were switched from calcitriol to alphacalcidol or vice versa and 29 patients (0.4%) received only alphacalcidol (Etalpha, Leo Pharma Inc., Plantation, Florida, US). Patients receiving oral active vitamin D for a period of less than 1 month (n ¼ 598) were considered nonusers of oral active vitamin D for analysis purposes. Of patients who were treated with oral active vitamin D, 53% had started treatment within 90 days of initiating chronic hemodialysis, 69% within 180 days, and 85% within 365 days; the remaining 15% had started treatment after 1 year on hemodialysis. Oral active vitamin D exposure was studied as In order to assure compliance, centers provided the oral active vitamin D to each individual patient and ensured that patients swallowed it at the end of the hemodialysis session.
Standard univariate analyses (w 2 , t-tests, and Mann-Whitney U-test) were performed, and values were reported as percentages, mean and standard deviation or median, and the interquartile range for descriptive purposes. The primary analysis used both, the Kaplan-Meier curves to examine crude survival and the Cox proportional hazard ratios to estimate mortality rate ratios for oral vitamin D users vs nonusers. Patients contributed as persontime until they underwent kidney transplantation, voluntarily withdrew from chronic hemodialysis, or reached the end of the follow-up period, whichever occurred first. Stratum-specific hazard ratios were examined to test whether there was a statistically significant effect in each stratum. The Cox model included the following baseline variables: age, gender, history of diabetes, time on dialysis, vascular access, weight, blood levels of albumin, hemoglobin, creatinine, and delivered dose of dialysis (Kt/V). To provide a better estimate of exposure, average of baseline laboratory values were obtained from all data recorded within the 3 months prior to the follow-up.
Serum levels of calcium, phosphorus, and PTH (the latter measured by the Nichols Advantage Chemiluminescence intact assay) were included in the Cox model as time-dependent variables. Serum calcium, phosphorus, and PTH reflected baseline levels for patients who did not receive oral active vitamin D, whereas for patients who received it, the calcium, phosphorus, and PTH levels included in the model were those collected before the initiation of therapy.
In order to account for a possible country effect on the mortality rate, all the analyses were carried out after adjusting them by country. Comorbidities were classified according to the ICD-10 and grouped into vascular, neoplastic, infectious, respiratory, neurological, or diabetes according to the Table 3 .
Furthermore, in order to get an unbiased estimate of the treatment effects, we obtained propensity scores in logistic regression models using as covariates the differences in baseline characteristics. We divided the cohort in tertiles of propensity scores and examined the hazard ratio for mortality risk associated with oral active vitamin D treatment.
Secondary analysis. In addition to the study of oral active vitamin D intake as a dichotomous variable (yes vs no), the mean daily intake (total cumulative dose of vitamin D divided by the number of days on dialysis) of oral active vitamin D was analyzed and subdivided into four categories: less than a mean of 0.25 mg per day, between 0.25 and 0.50 mg per day, between 0.51 and 1 mg per day, and more than 1 mg per day. These categories were used to evaluate the relationship between the dose of oral active vitamin D and mortality.
All analyses of the data were carried out using SPSS version 12.0 for Windows. 
